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Family history is a major risk factor for myocardial infarction (MI). However, known gene variants associated
with MI cannot fully explain the genetic component of MI risk. We hypothesized that a gene-centric association
study that was not limited to candidate genes could identify novel genetic associations with MI. We studied 11,053
single-nucleotide polymorphisms (SNPs) in 6,891 genes, focusing on SNPs that could inﬂuence gene function to
increase the likelihood of identifying disease-causing gene variants. To minimize false-positive associations generated
by multiple testing, two studies were used to identify a limited number of nominally associated SNPs; a third study
tested the hypotheses that these SNPs are associated with MI. In the initial study (of 340 cases and 346 controls),
637 SNPs were associated with MI ( ); these were evaluated in a second study (of 445 cases and 606 controls),P ! .05
and 31 of the 637 SNPs were associated with MI ( ) and had the same risk allele as in the ﬁrst study. ForP ! .05
each of these 31 SNPs, we tested the hypothesis that it is associated with MI, using a third study (of 560 cases
and 891 controls). We found that four of these gene variants were associated with MI ( ; false-discovery rateP ! .05
!10%) and had the same risk allele as in the ﬁrst two studies. These gene variants encode the cytoskeletal protein
palladin (KIAA0992 [odds ratio (OR) 1.40]), a tyrosine kinase (ROS1 [OR 1.75]), and two G protein–coupled
receptors (TAS2R50 [OR 1.58] and OR13G1 [OR 1.40]); all ORs are for carriers of two versus zero risk alleles.
These ﬁndings could lead to a better understanding of MI pathophysiology and improved patient risk assessment.
Introduction
Myocardial infarction (MI) is a prevalent and often fatal
manifestation of coronary heart disease.MI occurswhen
thrombosis, induced by a ruptured or eroded athero-
sclerotic plaque, occludes a coronary artery, which leads
to necrosis of the myocardium. Because of the high preva-
lence of risk factors, each year, ∼865,000 Americans are
diagnosed with MI and ∼180,000 will die from the dis-
ease (American Heart Association 2002).
MI is a complex disease with a strong genetic com-
ponent. Gene variants affecting traditional risk factors
forMI, such as hypertension, hypercholesterolemia, and
diabetes, have been described (reviewed by Lusis et al.
[2004]). Family history of disease is a risk factor inde-
pendent of traditional risk factors and is driven largely
by genetic variation (Shea et al. 1984; Marenberg et al.
1994). The complexity of MI is evidenced by the many
cell types that are involved in the formation of athero-
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sclerotic plaques (Faxon et al. 2004; Lusis et al. 2004)
and by the multiple processes that can affect risk of MI,
such as inﬂammation, plaque calciﬁcation, extracellular
matrix turnover, apoptosis, and thrombosis (Naghavi
et al. 2003). Given this complexity, it is not obvious
which genes will harbor the genetic variation responsi-
ble for the genetic component of MI.
Previous efforts to identify gene variants associated
with MI have included both linkage studies and case-
control association studies. Genomewide linkage studies
of coronary heart disease or MI have identiﬁed linkage
peaks in several chromosomal regions (reviewed by Lu-
sis et al. [2004]). However, detailed analysis of these
regions will be required to determine if they contain gene
variants involved in disease. Most case-control associa-
tion studies have focused on variants in genes related
to known risk factors for coronary heart disease. Gene
variants involved in dyslipidemia (e.g., apolipoprotein E
[APOE], low-density lipoprotein receptor [LDLR], apo-
lipoprotein(a) [LPA], and hepatic lipase [LIPC]) and
hypertension (e.g., angiotensinogen [AGT], angiotensin
converting enzyme [ACE], angiotensin II receptor, type
1 [AGTR1], and b2-adrenergic receptor [ADRB2]) have
been found to be associated with disease. Gene variants
have also shown association with MI in case-control
association studies of candidate genes selected on the
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Figure 1 Diagram of the process used to reduce the number of
hypotheses tested in subsequent studies. Study size and the number of
SNPs tested in each study are indicated. Only SNPs with unadjusted
P values !.05 for association with MI advanced to the next study.
Additionally, only SNPs with the same risk allele in study 1 and study
2 advanced to study 3. Six SNPs in study 3 had P values !.05 for
association with MI and an FDR !10%.
basis of disease pathophysiology. These include paroxo-
nase 1 (PON1), toll-like receptor 4 (TLR4), and matrix
metalloproteinase 3 (MMP3) (for recent reviews of can-
didate genes implicated in coronary heart disease, see
the works of Gibbons et al. [2004] and Lusis et al.
[2004]). The complex pathophysiology of MI suggests
the involvement of multiple genes; therefore, an exten-
sive search of human gene variants could lead to novel
associations with MI. Ozaki et al. (2002) conducted a
broad survey of 65,671 gene-based SNPs in a case-con-
trol association study of Japanese subjects and found
several SNPs in the lymphotoxin-a (LTA) gene to be
associated with MI. However, only 1,491 of the SNPs
in that survey were nonsynonymous SNPs, and it has
been suggested (Botstein and Risch 2003) that broad
association studies would beneﬁt from focusing on SNPs
that are likely to change protein function or expression.
It seems unlikely that those gene variants shown so
far to have convincing, reproducible association with
MI can fully explain the genetic component of risk for
MI. We therefore hypothesized that we could identify
novel gene variants associated with MI in an extensive
gene-centric association study that was not limited to
candidate genes. We reasoned that testing SNPs that
could inﬂuence gene function—for example, those af-
fecting the amino acid sequence of the encoded protein
or SNPs located in transcription-factor binding sites—
would increase the likelihood of identifying disease-
causing gene variants (Risch andMerikangas 1996; Bot-
stein and Risch 2003).
Material and Methods
Strategy
We conducted two sequential case-control studies
(study 1 and study 2) to identify SNPs putatively as-
sociated with MI and then a third study (study 3) to test
the hypotheses that these SNPs are associated with MI
(ﬁg. 1). This approach was used because of the difﬁ-
culties often encountered in reproducing reported SNP
associations with common complex diseases (Hirsch-
horn and Daly 2005). In study 1, DNA samples from
cases and controls were pooled separately to increase the
number of SNPs that could be tested (Sham et al. 2002).
The allele frequency of each SNP was determined in
pools of DNA (Germer et al. 2000). SNPs associated
with MI in study 1 ( ) were evaluated in study 2P ! .05
by use of a similar pooling strategy. SNPs associatedwith
MI in study 2 ( ) and with the same risk allele asP ! .05
in study 1 were then tested for association with MI by
genotyping individual DNA samples of study 3 subjects.
Since testing multiple SNPs in study 3 could have led to
false-positive associations due to multiple testing, we es-
timated the false-discovery rate (FDR) in study 3 and
used an FDR of !10% as a criterion for further analysis
of SNPs associated with disease. The three studies in-
cluded only whites, to minimize the likelihood of popu-
lation stratiﬁcation.
SNP Selection
We determined the allele frequency of 11,053 SNPs
(in 6,891 genes) in study 1. These SNPs are located in
genes and have the potential to affect gene function or
expression. The majority (7,496) of these SNPs are non-
synonymous SNPs, expected to modify the amino acid
sequence encoded by the gene. Other SNPs are located
in transcription-factor binding sites or in UTRs ofmRNA,
which we reasoned could affect mRNA expression or
stability. The SNPs tested were selected from public da-
tabases, from the Celera database (see the Applied Bio-
systems Web site), and from SNPs identiﬁed by sequence
analysis of ∼24,000 genes in 39 individuals (Clark et al.
2003). We excluded SNPs that had !1% allele frequency
in a white population, as well as SNPs that were de-
scribed in a single public database and lacked white al-
lele-frequency information.
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Allele Frequency and Genotype Determination
Allele frequencies in pooled DNA were determined by
kinetic PCR (Germer et al. 2000). In brief, DNA concen-
trations were standardized to 10 ng/ml with use of Pico-
Green (Molecular Probes) ﬂuorescent dye (Singer et al.
1997). DNA pools, typically from 50 cases or controls,
were made by mixing equal volumes of standardized
DNA from each individual member of the pool. With 3
ng of pooled DNA, one of two allele-speciﬁc primers,
and a common reverse primer, each allele was ampliﬁed
separately by PCR with use of an Applied Biosystems
PRISM 7900HT Sequence Detection System. The allele
frequency was calculated from the two allele-speciﬁc
PCR ampliﬁcation curves (Germer et al. 2000) on the
basis of at least eight independent pools of DNA, each
determined in duplicate. Individual genotyping was simi-
larly performed using 0.3 ng of DNA. All genotyping
was performed at the Celera Diagnostics high-through-
put genotyping facility. Genotyping accuracy in this fa-
cility is typically 199%, as reported elsewhere (Li et al.
2004). The genotyping accuracy for the four gene vari-
ants reported here was conﬁrmed to be 199.5%, by re-
peat genotyping of samples from study 3 with use of an
oligonucleotide ligation assay, which is an independent
genotyping technology.
Subjects
Cases had a history of MI; controls had no history of
MI. Since genetic makeup is a more important MI risk
factor in younger than in older individuals (Marenberg
et al. 1994), we preferentially recruited cases who ex-
perienced an MI at a young age. Participants in study 1
(males) and study 3 (males and females) were enrolled
between July 1989 and October 2003 by the University
of California–San Francisco (UCSF) Genomic Resource
in Arteriosclerosis. Participants included patients who
underwent diagnostic or interventional cardiac catheteri-
zation, patients of the UCSF Lipid Clinic, and healthy
older individuals. Participants in study 2 (males and fe-
males) were patients of the Cleveland Clinic Foundation
Heart Center who had undergone diagnostic or inter-
ventional cardiac catheterization between July 2001 and
March 2003. All subjects gave informed consent and
completed an institutional review board–approved ques-
tionnaire. All subjects chose “white” as their ethnicity
in response to a multiple-choice questionnaire; subjects
who chose “Hispanic” or other nonwhite ethnicities were
excluded from the study.
Study 1 subjects were aged !75 years. Cases had a
history of MI, as deﬁned by The International Classiﬁ-
cation of Diseases, 9th Revision (ICD9) codes for MI
(codes 410 or 411); by a clinical chart review; or by a
self-reported history. An ongoing effort by UCSF phy-
sicians to obtain clinical veriﬁcation of the MI status for
patients who had self-reported an MI has resulted in
198% veriﬁcation. Controls had no history of MI or
unstable angina. Most controls (95%) had undergone
cardiac catheterization, and 63% of the controls had
stable angina.
Study 2 cases were males aged !66 years and females
aged !75 years who had a history of MI that had been
veriﬁed by electrocardiogram, cardiac enzymes, or per-
fusion imaging. Controls had no history of MI and had
!50% coronary luminal narrowing, on the basis of clini-
cal angiography, and 81% had stable angina.
Study 3 cases had a history of MI veriﬁed by ICD9
codes for MI (codes 410 or 411) or a clinical chart re-
view. Controls had no history of MI, symptomatic vas-
cular disease, or diabetes and did not have a known ﬁrst-
degree relative with a history of symptomatic coronary
disease prior to age 65 years; 10% of the controls had
undergone cardiac catheterization. Since we had no way
of knowing whether young controls in the study would
confound the analysis by experiencing an MI shortly
after their recruitment, we recruited older individuals for
the study 3 control group (see table 1).
Statistical Analysis
The Wilcoxon rank sum test was used to assess as-
sociations between continuous phenotypes and disease
status, and the Kruskal-Wallis test was used to assess
associations of continuous phenotypes with genotypes.
Differences of proportions for categorical phenotypes
and association between MI status and allele frequencies
were assessed by two-tailed Fisher’s exact tests. Associa-
tions between diabetes status and MI risk-allele frequen-
cies were assessed by one-tailed Fisher’s exact tests. The
exact tests for pooled allele frequencies were performed
by rounding the estimated allele counts to the nearest
integer. Assessment of genotypic association, including
comparisons of risk homozygotes to heterozygotes aswell
as adjustment of odds ratios (ORs) for other covariables,
was performed using logistic regression. P values from
logistic regression were calculated using aWald test. Two-
sided P values are presented for comparisons of risk ho-
mozygotes to heterozygotes. One-sided P values are pre-
sented for study 3 results when the a priori hypothesis
was that the risk allele for the association matches the
risk allele observed in the previous two studies. Values
in the FDR column reported in table 2, denoted here
by Qi for the ith value in increasing order, were cal-
culated using the MULTTEST procedure (Benjamini
and Hochberg 1995) as follows: given m hypotheses
and corresponding P values ,H ,H ,… ,H P ,P ,… ,P1 2 m 1 2 m
the P values are ordered such that .P  P …  Pm (m1) 1
Then let Q p P ,Q p min (Q ,P #[m (mm m (m1) m (m1)
1)]), … ,Q p min (Q ,P # [m (m j)]),(mj) (mj1) (mj)
. Population stratiﬁcation was… ,Q p min (Q ,m# P )1 2 1
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Table 1
Distribution of Traditional MI Risk Factors
CHARACTERISTICS













Percentage male 100 100 62 62 45 37a
Age (years) 63 10 6110a 60 7 59 10 62 10 6613a
Age (in years) at MI 54 10 NA 5310b NA 52 9 NA
Percentage with smoking history 66 60 74 54c 65 43c
Percentage with diabetes 22 14a 39 10c 20 0d
Percentage with dyslipidemiae 86 76c 97 57c 83 53c
Percentage with hypertensionf 59 52 96 78c 62 33c
BMI (kg/m2) 28 5 27 5 31 6 c30 7 28 6 265c
NOTE.—Plus-minus () values are .mean SD
a for comparison with cases.P ! .01
b Data available for 240 cases.
c for comparison with cases.P ! .001
d Individuals with diabetes were excluded from control group.
e Dyslipidemia was deﬁned by use of lipid-lowering prescription drug(s), low-density lipoprotein cholesterol1129
mg/dl, triglyceride 1149 mg/dl, high-density lipoprotein !45 mg/dl, or a self-reported history of a physician diagnosis
of dyslipidemia.
f Hypertension was deﬁned by use of antihypertensive prescription drug(s), systolic blood pressure 1160, diastolic
blood pressure 190, or a self-reported history of a physician diagnosis of hypertension.
assessed by randomly drawing 1,000 SNPs from among
the 11,053 SNPs evaluated in study 1 and then by using
the method of Reich and Goldstein (2001) to estimate
an inﬂation factor l for the x2 test statistic. We repeated
this random draw 100 times, and we report the mean
l from the 100 draws. We report an approximate 95%
CI for l that extends 1.96 times the SD of l on either
side of the mean.
Results
Study Populations
The prevalence of traditional risk factors was gener-
ally higher in theMI case group than in the control group
in all three studies (table 1). In study 1, cases were sig-
niﬁcantly older than controls and the prevalence of dys-
lipidemia and diabetes was signiﬁcantly higher in the case
group than in the control group. BMI and the prevalence
of hypertension and smoking trended higher. In study
1, we investigated potential population stratiﬁcation,
which could inﬂuence the matching of the case and con-
trol samples, and found no signiﬁcant evidence of strati-
ﬁcation—the x2 test statistic inﬂation factor was not sig-
niﬁcantly different from 1.0 ( ; 95% CI .96–lp 1.06
1.16). In study 2, BMI and the prevalence of smoking,
diabetes, dyslipidemia, and hypertension were signiﬁ-
cantly higher in the case group than in the control group.
In study 3, BMI and the prevalence of smoking, dysli-
pidemia, and hypertension were signiﬁcantly higher in
the case group than in the control group. The mean age
was higher in the study 3 control group than in the study
3 case group because of the recruitment of older con-
trols. In all three studies, the mean age at MI was !55
years, which reﬂects the preferential enrollment of cases
who experienced an MI at a young age.
Gene Variants Associated with MI
In study 1, the ﬁrst hypotheses-generating study, we
tested which of 11,053 SNPs were associated with MI
by comparing the allele frequency of each SNP in cases
with the frequency in controls. We identiﬁed 637 of these
SNPs (in 593 genes) as candidates for further investiga-
tion in study 2, using an unadjusted P value of !.05 for
association with MI as the selection criterion (ﬁg. 1; see
the authors’ Web site for a supplemental PDF docu-
ment). We then used study 2, the second hypotheses-
generating study, to identify the set of SNPs to be tested
in study 3, the hypotheses-testing study. The criteria used
to select SNPs for study 3 were that the SNPs had the
same risk allele in both study 1 and study 2 and also had
an unadjusted P value of !.05 in both studies. We found
that 31 of the 637 SNPs met these criteria. These 31
SNPs are located in 30 different genes (table 2). Two of
the SNPs tested in study 2 had been reported elsewhere
to be associated with coronary heart disease—rs1041981
in LTA (Ozaki et al. 2002) and rs3732563 in AGTR1
(Jones et al. 2003). However, the LTA andAGTR1 SNPs
had unadjusted P values 1.7 in study 2 and thereforewere
not tested in study 3.
For each of the 31 SNPs we identiﬁed in study 2, we
tested, in study 3, the hypothesis that the SNP is asso-
ciated with MI. Since the putative risk allele of each of
these 31 SNPs had been identiﬁed in the hypotheses-
generating portion of this investigation (study 1 and study
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Table 2
FDR for SNPs Tested in Study 3
SNP GENE
P
FDRStudy 2a Study 3b
rs1376251 TAS2R50 .013 .0018 .03
rs12510359 KIAA0992/palladin .006 .0028 .03
rs4804611 ZNF627 .013 .0034 .03
rs529038 ROS1 .010 .0067 NAc
rs619203 ROS1 .022 .012 .07
rs1151640 OR13G1 .009 .013 .07
rs2290526 TOX .023 .048 .23
rs3776096 PCDHB6 .002 .09 .35
Chromosome 10:103890719 G/Ad PPRC1 .049 .10 .35
rs1799883 FABP2 .014 .13 .40
rs1861956 FLJ40217 .035 .14 .40
rs10455 CYBRD1 .040 .18 .41
rs707602 TPM1 .003 .18 .41
Chromosome 15:39585434 C/Td ITPKA .039 .19 .41
rs3820594 SYT11 .036 .23 .47
rs3129272 HLA-DPB2 .039 .31 .61
rs6691840 GRIK3 .007 .37 .66
rs1054735 FLJ45300 .015 .42 .66
rs11955611 FLJ46010 .036 .42 .66
rs236212 Nonee .046 .44 .66
rs4875 MLF1 .024 .46 .66
rs2747701 KIAA1411 .038 .51 .70
rs2240089 COBL .005 .55 .73
rs6788438 LXN .006 .56 NAc
rs6512265 LRRC25 .003 .62 .78
rs7905784 MCM10 .009 .77 .93
Chromosome 17:2174405 G/Td FLJ10534 .036 .89 .95
rs6546 C1QTNF3 .008 .92 .95
rs1611775 KCNA7 .015 .93 .95
rs11117358 BANP .029 .94 .95
rs1124649 FLJ20254 .021 .95 .95
a Two-sided P value for allelic association.
b One-sided P value for allelic association, with use of the same risk allele as in study
1 and study 2.
c Excluded from FDR calculation (see the “Gene Variants Associated with MI” section
for details).
d Build 35 chromosomal locations given for non-dbSNP numbers.
e Not in a gene in Build 35.
2), we tested, in study 3, the speciﬁc hypothesis that the
same risk allele is associated with risk of MI. For FDR
calculations, we considered only 29 of the 31 SNPs
tested in study 3, for the following reasons. The two
SNPs in ROS1 on chromosome 6 were not independent
of one another. They were concordant in all but four
individuals in study 3; that is, each individual was a
minor homozygote for both SNPs, a major homozygote
for both SNPs, or a heterozygote for both SNPs, so we
included only one (rs619203) in FDR calculations and
in subsequent analyses. Similarly, two SNPs on chromo-
some 3 (rs4875 and rs6788438) are only 67 kb apart
and were discordant in only ﬁve individuals in study 3;
we included only one of these SNPs in FDR calculations.
The SNPs with an FDR !10%were in palladin, a cyto-
skeletal protein (KIAA0992 [MIM 608092]), a tyrosine
kinase (ROS1 [MIM 165020], 2 SNPs), two G protein-
coupled receptors (TAS2R50 and OR13G1), and a zinc
ﬁnger protein (ZNF627) (table 3). Four of the six SNPs
cause amino acid residue substitutions. The SNP in pal-
ladin is located in an intron, and the SNP in ZNF627
is located in the 3′ UTR of the gene. Each SNP had the
same risk allele as well as a similar magnitude of risk in
all three studies (table 4).
MI Risk Associated with Genotypes
We estimated the risk of MI associated with each geno-
type of the ﬁve gene variants described in table 4. Since
the data did not support the use of a dominant, additive,
or recessive model for all of these SNPs, we show only
genotypic results for all SNPs, to provide a uniform pre-
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Table 3
Characteristics of SNPs Associated with MI
RefSNP Number Gene Name Chromosome
Base
Changea SNP Type
rs12510359 KIAA0992/palladin 4 G/A Intron
rs529038 ROS1 6 A/G Asn2213Asp
rs619203 ROS1 6 G/C Cys2229Ser
rs1376251 TAS2R50 12 C/T Cys203Tyr
rs1151640 OR13G1 1 A/G Ile132Val
rs4804611 ZNF627 19 A/G 3′ UTR
a The ﬁrst nucleotide is the major allele in this study.
sentation. When a particular genetic model could have
been justiﬁed, a model-based analysis would have re-
sulted in lower P values. Carriers of one or two risk
alleles of the ZNF627 SNP were at a signiﬁcantly in-
creased risk of MI versus those who did not carry a risk
allele. Likewise, carriers of one or two risk alleles of the
OR13G1 SNP were at a signiﬁcantly increased risk of
MI versus those who did not carry a risk allele (table
5). The difference in risk between the two risk genotypes
was not signiﬁcant ( for ZNF627; forPp .30 Pp .66
OR13G1); thus, the heterozygotes as well as the risk
homozygotes were at similar and signiﬁcantly increased
risk of MI. In the case of the TAS2R50, palladin, and
ROS1 variants, the risk of MI for carriers of two risk
alleles was greater than the risk for carriers of one risk
allele (for comparison ofMI risk of the risk homozygotes
vs. the heterozygote reference group, for pal-Pp .002
ladin; for TAS2R50; for ROS1).Pp .03 Pp .08
We investigated whether the risk associated with each
of these ﬁve gene variants was confounded by either
traditional risk factors or the other four gene variants.
Using multivariate analysis, we estimated the risk asso-
ciated with each genotype, after adjustment for ﬁve tra-
ditional risk factors: dyslipidemia, sex, smoking history,
hypertension, and BMI (table 5). Adjustment of the ge-
notypic risk for traditional risk factors, either alone or
in addition to the other four gene variants, resulted in
modest changes in the risk estimates for these SNPs (all
resultant adjusted P values were !.1). Since we had in-
tentionally selected controls who were somewhat older
than the cases in study 3, we asked whether age was
associated with any of the ﬁve SNPs in the control group.
We found an association of young age with the risk allele
of the SNP inZNF627 ( ). The other four SNPsPp .0005
were not associated with age (all P values were 1.24).
Similarly, since we selected controls for study 3 who did
not have diabetes, we asked whether the MI risk allele
of any of the ﬁve SNPs was associated with diabetes in
the case group of study 3. We found that there was a
trend toward association with diabetes for the MI risk
allele of the SNP inOR13G1 ( ). The associationPp .16
of this SNP with MI remained signiﬁcant ( ) afterP ! .05
exclusion of all subjects with diabetes from the analysis.
The MI risk alleles of the other four SNPs were not
associated with diabetes (all P values were 1.45).
Discussion
We identiﬁed four novel gene variants associated
with MI. They encode a cytoskeletal protein (palladin
[KIAA0992]), a tyrosine kinase (ROS1), and two G pro-
tein–coupled receptors (TAS2R50 andOR13G1). These
genes have not been previously reported to be associated
with MI and are not typical candidate genes for cardio-
vascular disease—which indicates the potential value of
unbiased, gene-centric genetic association studies in the
search for novel insights into cardiovascular disease
pathogenesis.
Association studies that test thousands of SNPs with-
out multiple-testing correction can lead to false-positive
associations, whereas a conservative correction can lead
to false-negative associations. We addressed this multi-
ple-testing dilemma by interrogating a smaller number
of SNPs in each of three successive studies and calcu-
lating the FDR for the SNPs tested in the third study.
We used an FDR of 10% as a criterion for further analy-
sis. The six SNPs with the lowest P values met this FDR
criterion of 10% in study 3. The FDRs reported in table
2 were calculated by the method of Benjamini andHoch-
berg (1995); however, a simple, intuitive way to estimate
the FDR of the six most signiﬁcant SNPs is to estimate
the number of expected false-positive SNPs and divide
it by the observed number of SNPs. Multiplying the
number of independent SNPs tested (29) by the highest
P value (.013) in the group of the six most signiﬁcant
SNPs gives the expected number of false-positive SNPs
( ). The observed number of indepen-29# .013p 0.377
dent SNPs was ﬁve (excluding one of the two SNPs in
ROS1); thus, the FDR estimate for the group estimated
by this simpliﬁed method would be 0.075 (0.38 5p
).0.075
Mindful of the fact that conventional risk factors were
enriched in the case groups as compared with the con-
trol groups, we investigated confounding by traditional
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Table 4
Allelic Association with MI in Three Studies
GENE NAME (SNP)
STUDY 1 STUDY 2 STUDY 3
ORa (95% CI) Pb OR (95% CI) Pb OR (90% CI)c Pd
KIAA0992/palladin (rs12510359) 1.28 (1.02–1.59) .031 1.29 (1.07–1.55) .006 1.25 (1.10–1.43) .0028
ROS1 (rs619203) 1.28 (1.01–1.64) .046 1.34 (1.08–1.66) .010 1.23 (1.06–1.42) .012
TAS2R50 (rs1376251) 1.27 (1.01–1.59) .049 1.27 (1.05–1.54) .013 1.28 (1.11–1.46) .0018
OR13G1 (rs1151640) 1.26 (1.01–1.55) .034 1.27 (1.06–1.50) .009 1.19 (1.05–1.36) .013
ZNF627 (rs4804611) 1.33 (1.05–1.68) .019 1.29 (1.06–1.57) .013 1.25 (1.09–1.44) .0034
a The reference allele was chosen such that the OR would be 11 in study 1; the same reference allele was then used
in study 2 and study 3.
b Two-sided Fisher’s exact test for allelic association.
c 90% CIs are presented to be consistent with the one-sided P values.
d One-sided Fisher’s exact test for allelic association.
risk factors. With use of multivariate analysis to adjust
for dyslipidemia, sex, smoking history, hypertension,
and BMI, none of these risk factors was found to be a
strong confounder for the associations observed in study
3. Similarly, the risk estimates for each of these SNPs
were only incrementally changed when adjusted for the
risk associated with the other four gene variants. When
association with age was evaluated in the study 3 con-
trol group, the putative MI risk allele of the SNP in
ZNF627 was associated with young age; thus, the ap-
parent association of this SNP with MI could be an
artifact caused by the preferential recruitment of older
controls, who were less likely to have the risk allele.
However, one possible explanation for the association
of the risk allele with young age would be that carriers
of this allele have a shorter life expectancy, which could
be due to increased risk of MI or some other disease.
None of the other SNPs was associated with age. We
also found that the MI risk allele of OR13G1 trended
toward associationwith diabetes.However, theOR13G1
SNP remained associated with MI when subjects with
diabetes were excluded from the case group, making
it unlikely that the association of OR13G1 with MI is
an artifact of selecting controls without diabetes for
study 3. These results suggest that the palladin, ROS1,
TAS2R50, and OR13G1 variants are associated with
MI and that these associations are not confounded
by dyslipidemia, hypertension, BMI, sex, or smoking
history.
The presumed function of these genes gives some hints
as to how they may be associated with MI; however,
the precise biological mechanism that underlies these
associations is unknown. For instance, palladin is a cy-
toskeletal protein that interacts with a-actinin and lo-
calizes to stress ﬁbers, focal adhesions, and cell-cell junc-
tions (Parast andOtey 2000; Ronty et al. 2004). A change
in palladin expression or function could affect endothe-
lial cell junctions, mononuclear cell trafﬁcking into ar-
terial walls, or platelet adhesion. ROS1, a receptor ty-
rosine kinase and a proto-oncogene (Birchmeier et al.
1987), is involved in cell proliferation and differentia-
tion (Zong et al. 1997) and is expressed at low levels
in most tissues (Boon et al. 2002); changes in cell pro-
liferation could affect arterial plaque formation and sta-
bility. The underlying biological mechanisms for the as-
sociation of the G protein–coupled receptors we de-
scribe (TAS2R50 andOR13G1) are not clear. However,
TAS2R50 is a bitter taste–receptor homolog (Conte et
al. 2003). Duffy et al. (2004) suggested that this family
of receptors may contribute to the risk of cardiovascular
disease by inﬂuencing dietary choices. Similarly, the as-
sociation with MI of OR13G1, an olfactory receptor
homolog, might be mediated through altered dietary
preferences.
The association of some of these ﬁve SNPs with MI
might be explained by linkage disequilibriumwith other
SNPs. In the case of palladin, ROS1, and OR13G1, the
haplotype-block structure reported by the International
HapMap Project (International HapMap Consortium
2003) indicates that these SNPs are located in haplotype
blocks that do not encompass other genes. Thus, the
available linkage data are consistent with the hypothe-
sis that the variants that contribute to risk of MI are
located within these three genes. In contrast, the SNP
in TAS2R50 is located in a haplotype block of ∼500
kb that contains 13 taste-receptor homologs as well
as three genes encoding proline-rich proteins. This raises
the possibility that the risk of MI associated with the
TAS2R50 SNP could be due to a SNP in one of these
other genes.
It has been suggested that population stratiﬁcation
could confound the interpretation of case-control stud-
ies (Marchini et al. 2004). To reduce potential confound-
ing of our results by population stratiﬁcation, we stud-
ied only self-described white individuals, because several
studies have reported only modest population stratiﬁca-
tion in white populations (Hao et al. 2004; Marchini et
al. 2004; Helgason et al. 2005). Additionally, we con-
ducted three different studies and enrolled the subjects
at two independent sites. Thus, if the associations we
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Table 5










Case Control ORc Pd OR Pd OR Pd
KIAA092/palladin:
AA 73 (13.1) 132 (14.9)
GA 233 (41.7) 430 (48.4) .98 .47 .97 .56 .94 .62
GG 253 (45.3) 326 (36.7) 1.40 .024 1.39 .04 1.35 .07
ROS1:
GG 298 (54.1) 522 (58.9)
GC 213 (38.7) 324 (36.6) 1.15 .11 1.21 .078 1.21 .09
CC 40 (7.3) 40 (4.5) 1.75 .010 1.54 .051 1.49 .07
TAS2R50:
TT 54 (9.8) 116 (13.1)
CT 226 (40.9) 396 (44.8) 1.23 .14 1.06 .39 1.09 .34
CC 273 (49.4) 372 (42.1) 1.58 .007 1.37 .06 1.40 .06
OR13G1:
AA 154 (27. 8) 293 (34.0)
AG 286 (51.7) 416 (48.2) 1.31 .017 1.26 .056 1.37 .002
GG 113 (20.4) 154 (17.8) 1.40 .019 1.39 .036 1.40 .04
ZNF627:
GG 49 (8.8) 118 (13.4)
AG 224 (40.1) 359 (40.7) 1.50 .018 1.63 .014 1.57 .02
AA 285 (51.1) 405 (45.9) 1.69 .002 1.95 .001 1.99 .001
a Dyslipidemia, sex, smoking history, hypertension, and BMI.
b Adjusted for risk factors and the other SNPs in this table.
c The reference allele was chosen such that the OR would be 11 in study 1; the same reference
allele was then used in study 2 and study 3.
d One-sided Wald test P value.
observed were caused by population stratiﬁcation, the
stratiﬁcation would have to have been of similar mag-
nitude and direction in all three studies. We also esti-
mated the potential magnitude of population stratiﬁca-
tion, using an inﬂation factor (l) for the x2 test statistic
to estimate population stratiﬁcation in study 1, and
found no signiﬁcant evidence of stratiﬁcation. Thus, it
seems unlikely that the associations we observed be-
tween MI and the genetic variants reported here can be
explained by population stratiﬁcation.
Several limitations were imposed by the samples used
in this investigation. Subjects with a history of MI were
recruited after the qualifying event. This introduced a
survival bias; consequently, gene variants most strongly
associated with fatal MI might not have been detected
in this case-control study. In addition, study 1 subjects
were all males; hence, it is unlikely that genetic markers
that are primarily associated with MI in females would
have been discovered in this study. The prevalence of
traditional risk factors differed between cases and con-
trols in all three studies (table 1), suggesting that dif-
ferences in the prevalence of genetic risk factors could
also be detectable in these studies. However, because of
the retrospective nature of these studies, the traditional
risk status prior toMI was typically not available, which
may have resulted in overreporting traditional risk fac-
tors in the case group. Thus, a complete understanding
of the relationship of traditional risk factors to the ob-
served associations should be sought in a population-
based cohort study. Nevertheless, the associations we
identiﬁed could be a step toward an improved under-
standing of disease regardless of whether adjustment for
traditional risk factors indicates that these novel associa-
tions contribute to pathways involving traditional risk
factors or to other aspects of disease pathophysiology.
MI is a prevalent disease with high morbidity and
mortality. However, changes in lifestyle as well as phar-
macological intervention can markedly reduce an in-
dividual’s risk. Thus, better estimates of an individual’s
risk could lead to more effective prevention and treat-
ment. In this study, we have observed the association of
four gene variants with MI. If conﬁrmed in prospective,
population-based studies, these markers—individually
or in combination—may be useful in identifying indi-
viduals at a risk for MI higher than that predicted by
traditional risk factors alone. Moreover, the SNPs we
identiﬁed are located in genes that have not been pre-
viously implicated in coronary heart disease. Thus, in-
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vestigation of the function of these genes in the context
of coronary heart disease could lead to a better under-
standing of the pathophysiology of this complex disease
and to new therapeutic strategies.
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